You are here » Home » Companies » Company Overview » Granules India Ltd

Granules India Ltd.

BSE: 532482 Sector: Health care
NSE: GRANULES ISIN Code: INE101D01020
BSE LIVE 15:43 | 18 Aug 126.75 -0.05
(-0.04%)
OPEN

126.00

HIGH

127.90

LOW

124.25

NSE 15:54 | 18 Aug 126.95 0.15
(0.12%)
OPEN

125.05

HIGH

128.00

LOW

124.25

OPEN 126.00
PREVIOUS CLOSE 126.80
VOLUME 113672
52-Week high 157.00
52-Week low 91.45
P/E 20.31
Mkt Cap.(Rs cr) 2,901
Buy Price 0.00
Buy Qty 0.00
Sell Price 126.75
Sell Qty 850.00
OPEN 126.00
CLOSE 126.80
VOLUME 113672
52-Week high 157.00
52-Week low 91.45
P/E 20.31
Mkt Cap.(Rs cr) 2,901
Buy Price 0.00
Buy Qty 0.00
Sell Price 126.75
Sell Qty 850.00

Granules India Ltd. (GRANULES) - Company History

Incorporated as a private limited company in 1991, Granules India (GIL) was converted into a public limited company in Feb.'93. It commenced its operations in Apr.'91 as a merchant exporter of bulk drugs like paracetamol, guaifenesin and chloro pheniramine maleate. The company exports to the US, Europe, Mexico and Hongkong. Since 1992, GIL concentrated on export of paracetamol powder. In Aug.'94, GIL took over Triton Laboratories (TL), a group company from which GIL was procuring the drugs for exports. GIL also acquired a sick unit which was manufacturing bulk drugs, from the Andhra Pradesh State Financial Corporation (APSFC) in Mar.'94. GIL implemented the ongoing project taken over from TL to manufacture bulk drugs like folic acid, salbutamol sulphate, brom pheniramine maleate and direct compression (DC) blends of paracetamol, through the process of granulation. The unit, an EOU, is located at Hyderabad, Andhra Pradesh. Commercial production of folic acid commenced in Aug.'95. It came out with a public issue in Sep.'95 to part-finance this project. Company has completed expansion of Guaifenesin capacity from 100 Mts to 240 Mts per annum. Company had developing new products like Brom Pheniramine Maleate & Chloro Pheniramine Maleate, & is in process of developing new bulk drug for the export market. Company is very much hopeful about company's performance due to expansion of project will be completed in the current year. The Company set up a 100% marketing subsidiary in US to enhance its exposure in the large pharmaceutical market in the world. The Gagillapur plant commences its commercial production of Line II(installed capacity 3200 MT) which was commenced its July,2003 and the remaining 4000 MTPA is expected to go on stream in the first half of 2003-04. The total project cost is Rs.30 crore.